Fast Five Quiz: Hidradenitis Suppurativa

William D. James, MD


November 05, 2019

While clinical guidelines provide recommendations to assist clinicians in making optimal treatment decisions for patients at all stages of disease, owing to the lack of rigorous evidence for most treatment modalities, there is no set standard of care treatment for patients with hidradenitis suppurativa. Therefore, both the North American clinical management guidelines and the European S1 guideline for the treatment of hidradenitis suppurativa recommend an individualized approach to treatment based on the subjective impact of the disease on the patient and the objective severity determined by the physician (eg, Hurley clinical staging classification).

Local excision coupled with systemic treatment is not the first-line approach to treating patients with hidradenitis suppurativa at all stages of disease, but rather is typically reserved for patients with severe and chronic disease.

Medical management of hidradenitis suppurativa is typically recommended in the early stages of disease.

Systemic biologics (adalimumab/infliximab) are not recommended as a first-line treatment for patients with mild to moderate hidradenitis suppurativa. Systemic biologics are typically reserved for patients with treatment-resistant, moderate to severe hidradenitis suppurativa.

For more on the treatment recommendations for hidradenitis suppurativa, read here and here.

Follow Medscape on Facebook, Twitter, Instagram, and YouTube


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.